Medication-related osteonecrosis of the jaw in a cancer patient receiving lenvatinib

Giuseppina Campisi, Vera Panzarella, Rodolfo Mauceri, Ilaria Morreale, Panzarella, Rodolfo Mauceri, Campisi, Ilaria Morreale

Risultato della ricerca: Articlepeer review

11 Citazioni (Scopus)


Medication-related osteonecrosis of the jaw (MRONJ) is an adverse drug reaction that affects the mandible and maxilla of patients exposed to bone-targeting agents such as anti-resorptive and anti-angiogenic agents. Several MRONJ cases have been reported after dental extractions in patients under treatment with anti-angiogenic agents, including receptor activator of nuclear factor κB ligand (RANKL) inhibitor, anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody, mammalian target of rapamycin (mTOR) inhibitors, and tyrosine kinase inhibitors (TKIs). The aim of this article was to describe an original case of lenvatinib-related osteonecrosis of the jaw in a patient affected by thyroid cancer. A 58-year-old man diagnosed with Hurthle cell thyroid cancer, who was undergoing treatment with lenvatinib, developed maxillary osteonecrosis after a dental extraction. No other concomitant local or systemic risk factors for MRONJ were present. With new cancer therapies applied every year, it is important to note this novel case of lenvatinib osteonecrosis of the jaw in a patient undergoing cancer treatment.
Lingua originaleEnglish
pagine (da-a)1530-1532
Numero di pagine3
RivistaInternational Journal of Oral and Maxillofacial Surgery
Stato di pubblicazionePublished - 2019

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2746???
  • ???subjectarea.asjc.3500.3504???
  • ???subjectarea.asjc.2700.2733???


Entra nei temi di ricerca di 'Medication-related osteonecrosis of the jaw in a cancer patient receiving lenvatinib'. Insieme formano una fingerprint unica.

Cita questo